title: Intravitreal bevacizumab in the treatment of diabetic ocular neovascularization.
abstract: OBJECTIVE
  To evaluate the efficacy of intravitreal bevacizumab for treating diabetic retinal and/or iris neovascularization.
  
  
  METHODS
  Consecutive, prospective, interventional case series study of 60 eyes with diabetic retinal and/or iris neovascularization. Patients had a complete ocular examination before receiving 1.25 mg (0.05 mL) of intravitreal bevacizumab. Abnormal new vessels elsewhere in the retina, optic disk, or iris were graded by size and associated hemorrhage or glaucoma. Patients had complete postinjection ophthalmic evaluations with regrading of the abnormal new vessels at 3 months and 6 months. The main outcome measures included clinical partial or total regression of abnormal new vessels, changes in visual acuity, and complications related to the intravitreal injections.
  
  
  RESULTS
  Twenty-six patients (47.3%) were men (mean age, 59 years). Abnormal new vessel regression at 6 months occurred in 65% of new vessels of the iris (P = 0.001), 45% of new vessels of the optic disk (P = 0.009), and 43% of new vessels elsewhere (P = 0.008). The visual acuity improved in 20% of eyes, which was not significant (P = 0.235); the visual acuity deteriorated in 23% of eyes (P = 0.163). No systemic or ocular side effects developed except for postinjection hypotony in one eye.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab is a well-tolerated medication that causes regression of abnormal diabetic neovascularization. New vessels of the iris responded more than new vessels of the optic disk and new vessels elsewhere.
authors.affiliation: Ophthalmology Department, Jordan University Hospital, The University of Jordan, Amman, Jordan. Ababneh99@yahoo.com
authors.forename: Osama H
authors.initials: OH
authors.lastname: Ababneh
authors.forename: Yacoub A
authors.initials: YA
authors.lastname: Yousef
authors.forename: Almutez M
authors.initials: AM
authors.lastname: Gharaibeh
authors.forename: Mohammed A
authors.initials: MA
authors.lastname: Abu Ameerh
authors.forename: Nakhleh E
authors.initials: NE
authors.lastname: Abu-Yaghi
authors.forename: Muawyah D
authors.initials: MD
authors.lastname: Al Bdour
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D058449:Intravitreal Injections; D007498:Iris / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009898:Optic Disk / Q000098:blood supply*; D011446:Prospective Studies; D015861:Retinal Neovascularization / Q000188:drug therapy; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab